Trial
NCT00797667
MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Migraine
Intervention
Telcagepant 140 mg
Why stopped
The study was terminated based on a recommendation of the DSMB following the identification of two patients with significant elevations in serum transaminases
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-18